Evidence map›Paper›PMID 40649782›Full record

ArticleInternational journal of molecular sciences2025

Resolvin D2 and Its Effects on the Intestinal Mucosa of Crohn's Disease Patients: A Promising Immune Modulation Therapeutic Target.

Livia Bitencourt Pascoal, Bruno Lima Rodrigues, Guilherme Augusto da Silva Nogueira, Maria de Lourdes Setsuko Ayrizono, Priscilla de Sene Portel Oliveira, Licio Augusto Velloso, Raquel Franco Leal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Livia Bitencourt PascoalInflammatory Bowel Disease Research Laboratory, Colorectal Surgery Unit, Gastrocenter, School of Medical Sciences, University of Campinas (Unicamp), São Paulo 13083-878, Brazil.ORCID 0000-0002-1109-5661
Bruno Lima RodriguesInflammatory Bowel Disease Research Laboratory, Colorectal Surgery Unit, Gastrocenter, School of Medical Sciences, University of Campinas (Unicamp), São Paulo 13083-878, Brazil.
Guilherme Augusto da Silva NogueiraLaboratory of Cell Signaling, Obesity and Comorbidities Research Center, School of Medical Sciences, University of Campinas (Unicamp), São Paulo 13083-878, Brazil.
Maria de Lourdes Setsuko AyrizonoInflammatory Bowel Disease Research Laboratory, Colorectal Surgery Unit, Gastrocenter, School of Medical Sciences, University of Campinas (Unicamp), São Paulo 13083-878, Brazil.
Priscilla de Sene Portel OliveiraInflammatory Bowel Disease Research Laboratory, Colorectal Surgery Unit, Gastrocenter, School of Medical Sciences, University of Campinas (Unicamp), São Paulo 13083-878, Brazil.ORCID 0000-0002-7519-2495
Licio Augusto VellosoLaboratory of Cell Signaling, Obesity and Comorbidities Research Center, School of Medical Sciences, University of Campinas (Unicamp), São Paulo 13083-878, Brazil.
Raquel Franco LealInflammatory Bowel Disease Research Laboratory, Colorectal Surgery Unit, Gastrocenter, School of Medical Sciences, University of Campinas (Unicamp), São Paulo 13083-878, Brazil.ORCID 0000-0003-4285-4402

Funding

Brazilian Coordination for the Improvement of Higher Education Personnel (CAPES Coor-denação de Aperfeiçoamento de Pessoal de Nível Superior, Brasil) Finance Code 001 for B.L.R.Funding for Education, Research and Extension Support (FAEPEX), University of Campinas #2332/20 for L.B.P.National Council for Scientific and Technological Development (CNPq) 302557/2021-0 for R.F.L.São Paulo Research Foundation (FAPESP) 2022/09393-4 for R.F.L.
6 · The paper itself

Abstract

Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract that severely impacts patients' quality of life. Although current therapies have improved symptom management, they often fail to alter disease progression and are associated with immunosuppressive side effects. This study evaluated the immunomodulatory potential of resolvin D2 (RvD2), a pro-resolving lipid mediator, using a murine model of colitis and the ex vivo treatment of intestinal mucosal biopsies from CD patients, comparing its effects to those of conventional anti-TNFα therapy. To determine the optimal concentration of RvD2 for application in human tissue explant cultures, an initial in vitro assay was conducted using intestinal biopsies from mice with experimentally induced colitis. The explants were treated in vitro with varying concentrations of RvD2, and 0.1 μM emerged as an effective dose. This concentration significantly reduced the transcriptional levels of TNF-α (

Indexed as

Crohn DiseaseDocosahexaenoic AcidsIntestinal MucosaAdultAnimalsDisease Models, AnimalFemaleHumansMaleMiceMiddle AgedTumor Necrosis Factor-alphaDocosahexaenoic Acidsresolvin D2Tumor Necrosis Factor-alphaCrohn’s diseaseimmunoregulationpro-resolving lipid mediatorresolvin D2

Identifiers

PMID40649782
PMCPMC12249623

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.